Latest Articles from Renaissance Capital

Aspen Aerogels withdraws $115 million IPO

Renaissance Capital — Sat, 18 May 2013 01:01:58 Z

Aspen Aerogels, which manufactures aerogel insulation principally used by petrochemical and power generation facilities, withdrew its plans for an initial public offering on Friday. The

FusionStorm Global officially withdraws IPO following 2011 postponement

Renaissance Capital — Sat, 18 May 2013 00:35:24 Z

FusionStorm Global, which offers diversified IT solutions to enterprises and the public sector, withdrew its plans for an initial public offering on Friday. FusionStorm initially filed for an

Tableau and Marketo push May US IPO pricings to 22, marking busiest month since November 2007

Renaissance Capital — Fri, 17 May 2013 20:06:32 Z

Tableau ( DATA ), which sells a data visualization platform, and Marketo ( MKTO ), a provider of marketing automation software, priced their IPOs last night, pushing total IPO pricings in

Tableau Software prices upsized IPO above the revised range at $31

Renaissance Capital — Fri, 17 May 2013 02:10:20 Z

Tableau Software, which provides interactive data visualization software, raised $254 million by offering 8.2 million shares at $31, above the revised range of $28 to $30. The company had

Marketo prices IPO at $13, at high end of the range

Renaissance Capital — Fri, 17 May 2013 01:56:36 Z

Marketo, which provides on-demand marketing software to SMBs and enterprises, raised $79 million by offering 6.1 million shares at $13, at the high end of the $11-$13 range.Marketo will list on

PTC Therapeutics files for a $85 million IPO following failed IPO attempt in 2006

Renaissance Capital — Fri, 17 May 2013 01:39:18 Z

PTC Therapeutics, which develops orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, filed on Thursday with the SEC to raise up to $85

William Lyon Homes prices IPO above the range at $25

Renaissance Capital — Thu, 16 May 2013 16:45:35 Z

William Lyon Homes, which is leading regional homebuilder in CA, AZ, NV and CO, raised $218 million by offering 8.7 million shares at $25, above the range of $22 to $24. William Lyon Homes

UBIC prices IPO at $8.38, within the range

Renaissance Capital — Thu, 16 May 2013 16:36:45 Z

UBIC, a provider of Asian-language software-based eDiscovery services, raised $9 million by offering 1.1 million shares at $8.38, within the range of $7.50 to $9.50. UBIC plans to list on the

Israeli therapeutics company Kamada sets terms for $60 million U.S. IPO

Renaissance Capital — Thu, 16 May 2013 07:51:57 Z

Kamada, which produces plasma-derived protein therapeutics, announced terms for its IPO on Wednesday. The Ness Ziona, Israel-based company plans to raise $60 million by offering 5.6 million

Ambit Biosciences prices IPO at $8

Renaissance Capital — Thu, 16 May 2013 02:48:12 Z

Ambit Biosciences, which is developing small molecule therapeutics for the treatment of acute myeloid leukemia, raised $65 million by offering 8.1 million shares at $8. Ambit Biosciences plans

Tableau Software increases price range for IPO, new deal size is $209 million

Renaissance Capital — Wed, 15 May 2013 21:24:41 Z

Tableau Software, which provides interactive data visualization software, raised the proposed deal size for its upcoming IPO on Wednesday. The Seattle, WA-based company now plans to raise $209

Ambit Biosciences revises terms for IPO, maintains $65 million deal size

Renaissance Capital — Wed, 15 May 2013 16:51:04 Z

Ambit Biosciences, which is developing small molecule therapeutics for the treatment of acute myeloid leukemia, revised the terms for its upcoming IPO on Wednesday, but maintained the total

Compuware's Covisint files for a $100 million IPO

Renaissance Capital — Wed, 15 May 2013 02:03:12 Z

Covisint, which provides secure, industry specific communication and collaboration platforms, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. The

Gene therapy biotech bluebird bio files for a $86 million IPO

Renaissance Capital — Wed, 15 May 2013 01:55:28 Z

bluebird bio, a clinical-stage biotech focused on treating severe genetic and orphan diseases with gene therapy, filed on Tuesday with the SEC to raise up to $86 million in an initial public

Esperion Therapeutics files for a $70 million IPO

Renaissance Capital — Wed, 15 May 2013 01:03:57 Z

Esperion Therapeutics, which is focused on the treatment for elevated levels of low-density lipoprotein cholesterol, filed on Tuesday with the SEC to raise up to $70 million in an initial